134 related articles for article (PubMed ID: 38061288)
1. Measures of functional status in older patients treated with palbociclib for advanced breast cancer.
Karuturi MS; Cappelleri JC; Blum JL; Patel K; Telivala B; McCune S; Cuevas JD; Lakhanpal S; Montelongo MZ; Wang Y; Tripathy D; Rocque GB
J Geriatr Oncol; 2024 Jan; 15(1):101670. PubMed ID: 38061288
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of male patients with HR+/HER2- advanced breast cancer receiving palbociclib in the real-world POLARIS study.
Blum JL; DiCristo C; Gordon D; Karuturi MS; Oubre D; Jepsen E; Cuevas J; Lakhanpal S; Montelongo MZ; Zhang Z; Cappelleri JC; Wang Y; Tripathy D
Breast Cancer Res Treat; 2024 Feb; 203(3):463-475. PubMed ID: 37903899
[TBL] [Abstract][Full Text] [Related]
3. Functional status in older patients with cancer and a frailty risk profile: A multicenter observational study.
Meert G; Kenis C; Milisen K; Debruyne PR; De Groof I; Focan C; Cornélis F; Verschaeve V; Bachmann C; Bron D; Den Bulck HV; Schrijvers D; Langenaeken C; Specenier P; Jerusalem G; Praet JP; Lobelle JP; Flamaing J; Wildiers H; Decoster L
J Geriatr Oncol; 2022 Nov; 13(8):1162-1171. PubMed ID: 36085275
[TBL] [Abstract][Full Text] [Related]
4. POLARIS: a prospective, multicenter, noninterventional study assessing palbociclib in hormone receptor-positive advanced breast cancer.
Tripathy D; Blum JL; Rocque GB; Bardia A; Karuturi MS; Cappelleri JC; Liu Y; Zhang Z; Davis KL; Wang Y
Future Oncol; 2020 Nov; 16(31):2475-2485. PubMed ID: 32787449
[TBL] [Abstract][Full Text] [Related]
5. Prospective evaluation of the G8 screening tool for prognostication of survival in elderly patients with lung cancer: A single-institution study.
Agemi Y; Shimokawa T; Sasaki J; Miyazaki K; Misumi Y; Sato A; Aida S; Ishii M; Nakamura Y; Naoki K; Okamoto H
PLoS One; 2019; 14(1):e0210499. PubMed ID: 30653558
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of baseline functional status measures and geriatric screening in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy - The randomized NORDIC9-study.
Liposits G; Ryg J; Skuladottir H; Winther SB; Möller S; Hofsli E; Shah CH; Poulsen LØ; Berglund Å; Qvortrup C; Osterlund P; Glimelius B; Sorbye H; Pfeiffer P
J Geriatr Oncol; 2023 Jan; 14(1):101408. PubMed ID: 36494261
[TBL] [Abstract][Full Text] [Related]
7. The G8 screening tool enhances prognostic value to ECOG performance status in elderly cancer patients: A retrospective, single institutional study.
Takahashi M; Takahashi M; Komine K; Yamada H; Kasahara Y; Chikamatsu S; Okita A; Ito S; Ouchi K; Okada Y; Imai H; Saijo K; Shirota H; Takahashi S; Mori T; Shimodaira H; Ishioka C
PLoS One; 2017; 12(6):e0179694. PubMed ID: 28640844
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3.
Rugo HS; Cristofanilli M; Loibl S; Harbeck N; DeMichele A; Iwata H; Park YH; Brufsky A; Theall KP; Huang X; McRoy L; Bananis E; Turner NC
Oncologist; 2021 Aug; 26(8):e1339-e1346. PubMed ID: 34037282
[TBL] [Abstract][Full Text] [Related]
9. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
Cristofanilli M; Turner NC; Bondarenko I; Ro J; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Zhang K; Theall KP; Jiang Y; Bartlett CH; Koehler M; Slamon D
Lancet Oncol; 2016 Apr; 17(4):425-439. PubMed ID: 26947331
[TBL] [Abstract][Full Text] [Related]
10. G8 and VES-13 as screening tools for geriatric assessment and predictors of survival in older Indian patients with cancer.
Shah M; Noronha V; Ramaswamy A; Gattani S; Mokal S; Joshi A; Patil V; Menon N; Banavali S; Badwe R; Prabhash K
J Geriatr Oncol; 2022 Jun; 13(5):720-730. PubMed ID: 35283049
[TBL] [Abstract][Full Text] [Related]
11. Value of geriatric screening and assessment in predicting postoperative complications in patients older than 70 years undergoing surgery for colorectal cancer.
Fagard K; Casaer J; Wolthuis A; Flamaing J; Milisen K; Lobelle JP; Wildiers H; Kenis C
J Geriatr Oncol; 2017 Sep; 8(5):320-327. PubMed ID: 28781062
[TBL] [Abstract][Full Text] [Related]
12. [Patients treated with palbociclib and endocrine therapy for metastatic breast cancer: Can we predict the occurrence of severe early hematological toxicity?].
Vazquez L; Arnaud A; Grenier J; Debourdeau P
Bull Cancer; 2021 May; 108(5):544-552. PubMed ID: 33820647
[TBL] [Abstract][Full Text] [Related]
13. External validation and diagnostic value of the Elderly Functional Index version 2.0 for assessing functional status and frailty in older Danish patients with gastrointestinal cancer receiving chemotherapy: A prospective, clinical study.
Jespersen E; Soo WK; Minet LR; Eshoj HR; King MT; Pfeiffer P; Möller S
J Geriatr Oncol; 2024 Jan; 15(1):101675. PubMed ID: 38070322
[TBL] [Abstract][Full Text] [Related]
14. Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment.
Bell T; Crown JP; Lang I; Bhattacharyya H; Zanotti G; Randolph S; Kim S; Huang X; Huang Bartlett C; Finn RS; Slamon D
Curr Med Res Opin; 2016 May; 32(5):959-65. PubMed ID: 26894413
[TBL] [Abstract][Full Text] [Related]
15. The Importance of a Detailed Geriatric Functional Assessment of Older Patients with Cancer.
Baumann C; Baumann R; Wedding U
Oncol Res Treat; 2021; 44(5):221-231. PubMed ID: 33910204
[TBL] [Abstract][Full Text] [Related]
16. Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer.
Lynce F; Blackburn MJ; Zhuo R; Gallagher C; Hahn OM; Abu-Khalaf M; Mohebtash M; Wu T; Pohlmann PR; Dilawari A; Tiwari SR; Chitalia A; Warren R; Tan M; Shajahan-Haq AN; Isaacs C
Cancer; 2021 Oct; 127(19):3622-3630. PubMed ID: 34157782
[TBL] [Abstract][Full Text] [Related]
17. Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer.
Porte B; Carton M; Lerebours F; Brain E; Loirat D; Haroun L; Bellesoeur A; Bach Hamba S; Kirova Y; Cottu P
Breast; 2020 Dec; 54():303-310. PubMed ID: 33242757
[TBL] [Abstract][Full Text] [Related]
18. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Finn RS; Crown JP; Lang I; Boer K; Bondarenko IM; Kulyk SO; Ettl J; Patel R; Pinter T; Schmidt M; Shparyk Y; Thummala AR; Voytko NL; Fowst C; Huang X; Kim ST; Randolph S; Slamon DJ
Lancet Oncol; 2015 Jan; 16(1):25-35. PubMed ID: 25524798
[TBL] [Abstract][Full Text] [Related]
19. Real-World Clinical Data of Palbociclib in Asian Metastatic Breast Cancer Patients: Experiences from Eight Institutions.
Lee J; Park HS; Won HS; Yang JH; Lee HY; Woo IS; Shin K; Hong JH; Yang YJ; Chun SH; Byun JH
Cancer Res Treat; 2021 Apr; 53(2):409-423. PubMed ID: 33138346
[TBL] [Abstract][Full Text] [Related]
20. Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies.
Ettl J; Im SA; Ro J; Masuda N; Colleoni M; Schnell P; Bananis E; Lu DR; Cristofanilli M; Rugo HS; Finn RS
Breast Cancer Res; 2020 Mar; 22(1):27. PubMed ID: 32164785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
